BGIM
YMAB

Brandywine Global Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Brandywine Global Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,468
Closed -$295K – 791
2022
Q3 		$295K Sell
20,468
-832
-4% -$13.8K ﹤0.01% 693
2022
Q2 		$322K Sell
21,300
-3,100
-13% -$36.2K ﹤0.01% 679
2022
Q1 		$290K Hold
24,400
– – ﹤0.01% 681
2021
Q4 		$396K Sell
24,400
-8,137
-25% -$174K ﹤0.01% 634
2021
Q3 		$929K Buy
+32,537
New +$1.03M 0.01% 574

Other funds holding YMAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brandywine Global Investment Management's YMAB Position: Q4 2022 in Review

Brandywine Global Investment Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 20,468 shares — an estimated $295K sold.

Brandywine Global Investment Management first reported a position in YMAB in Q3 2021 and held it in 5 quarters. The position peaked at $929K in Q3 2021. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Brandywine Global Investment Management reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Brandywine Global Investment Management sold 20,468 Y-mAbs Therapeutics shares in Q4 2022, an estimated $295K.
  • Brandywine Global Investment Management first reported a position in Y-mAbs Therapeutics in Q3 2021 and held it in 5 quarters.
  • Brandywine Global Investment Management's Y-mAbs Therapeutics position peaked at $929K in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Brandywine Global Investment Management's 13F filing for Q4 2022, filed 10 Feb 2023.